安罗替尼联合多西他赛二线治疗晚期非小细胞肺癌疗效观察

目的 观察晚期非小细胞肺癌患者应用安罗替尼联合多西他赛二线治疗后血清癌胚抗原(carcino-embryonic antigen,CEA)、血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)水平变化,探讨其治疗效果及安全性.方法 60例晚期非小细胞肺癌患者依据治疗方法...

Efficacy of anlotinib combined with docetaxel chemotherapy as second-line treatment on advanced non-small cell lung cancer

Objective To observe the changes of carcino-embryonic antigen(CEA)and serum vascular endothelial growth factor(VEGF)after the second-line treatment with anlotinib combined with docetaxel in patients with advanced non-small cell lung cancer,and to investigate the therapeutic effect and safety.Methods Sixty patients with advanced non-small cell lung cancer were equally divided into observation group and control group according to different treatment plan.Control group was given intravenous drip of docetaxel 75 mg/m~2 by day 1,totally for 21 days as one cycle,besides which observation group was given orally administration of anlotinib capsule 12 mg once a day by day 1 to 14,totally for 21 days as one cycle.The therapeutic effect was evaluated every two cycles.The treatment was terminated when the adverse reactions were intolerable or the disease was progressive.The levels of CEA and VEGF were detected in two groups before and after four-cycle chemotherapy.The disease control rate and objective effective rate were compared between two groups after four cycles.The progression-free survival time and the occurrence of adverse reactions were followed up and compared between two groups.Results The levels of CEA and VEGF were lower in observation group((7.25±4.93)μg/L,(56.12±33.69)ng/L)and control group((12.28±5.63)μg/L,(102.17±44.94)ng/L)after four-cycle chemotherapy than those before chemotherapy(observation group:(50.47±13.49)μg/L,(407.41±147.32)ng/L;control group:(54.15±12.93)μg/L,(411.44±143.56)ng/L)(P<0.05),and lower in observation group than those in control group(P<0.05).After four-cycle chemotherapy,the disease control rate was higher in observation group(86.67%)than that in control group(60.00%)(P<0.05),and the objective effective rate showed no significant difference between observation group(26.67%)and control group(20.00%)(P>0.05).Till April 30,2020,the median progression-free survival time was longer in observation group(4.8 months)than that in control group(2.8 months)(P<0.05).Most of the adverse reactions in two groups were gradeⅠtoⅡ,which were tolerable.The incidences of hand-foot syndrome,hypertension and haemoptysis were higher in observation group(36.67%,33.33%,13.33%)than those in control group(0,6.67%,0)(P<0.05).Conclusion The second-line treatment with anlotinib plus docetaxel in patients with advanced non-small cell lung cancer can lower the levels of tumor markers,improve the disease control rate,and prolong the progression-free survival time,and the adverse reactions are tolerable.